Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15,865 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of Ezetimibe on LDL-C Lowering and Atherogenic Lipoprotein Profiles in Type 2 Diabetic Patients Poorly Controlled by Statins.
Sakamoto K, Kawamura M, Kohro T, Omura M, Watanabe T, Ashidate K, Horiuchi T, Hara H, Sekine N, Chin R, Tsujino M, Hiyoshi T, Tagami M, Tanaka A, Mori Y, Inazawa T, Hirano T, Yamazaki T, Shiba T; RESEARCH Study Group. Sakamoto K, et al. Among authors: watanabe t. PLoS One. 2015 Sep 23;10(9):e0138332. doi: 10.1371/journal.pone.0138332. eCollection 2015. PLoS One. 2015. PMID: 26398887 Free PMC article. Clinical Trial.
Effect of ezetimibe add-on therapy over 52 weeks extension analysis of prospective randomized trial (RESEARCH study) in type 2 diabetes subjects.
Sakamoto K, Kawamura M, Watanabe T, Ashidate K, Kohro T, Tanaka A, Mori Y, Tagami M, Hirano T, Yamazaki T, Shiba T; RESEARCH Study Group. Sakamoto K, et al. Among authors: watanabe t. Lipids Health Dis. 2017 Jun 24;16(1):122. doi: 10.1186/s12944-017-0508-4. Lipids Health Dis. 2017. PMID: 28646901 Free PMC article. Clinical Trial.
Long-term safety and efficacy of alogliptin, a DPP-4 inhibitor, in patients with type 2 diabetes: a 3-year prospective, controlled, observational study (J-BRAND Registry).
Ueki K, Tanizawa Y, Nakamura J, Yamada Y, Inagaki N, Watada H, Shimomura I, Nishimura R, Miyoshi H, Abiko A, Katagiri H, Hayashi M, Shimada A, Naruse K, Fujimoto S, Fujiwara M, Shikata K, Okada Y, Araki E, Yamazaki T, Kadowaki T; J-BRAND Registry Group. Ueki K, et al. BMJ Open Diabetes Res Care. 2021 Jan;9(1):e001787. doi: 10.1136/bmjdrc-2020-001787. BMJ Open Diabetes Res Care. 2021. PMID: 33441417 Free PMC article.
Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia).
Seino Y, Min KW, Niemoeller E, Takami A; EFC10887 GETGOAL-L Asia Study Investigators. Seino Y, et al. Diabetes Obes Metab. 2012 Oct;14(10):910-7. doi: 10.1111/j.1463-1326.2012.01618.x. Epub 2012 May 30. Diabetes Obes Metab. 2012. PMID: 22564709 Free PMC article. Clinical Trial.
15,865 results
You have reached the last available page of results. Please see the User Guide for more information.